Ian Moore
Fortune : 77 744 $ au 30/06/2026
Fortune : 77 744 $ au 30/06/2026
Ian Roger Moore served as the Chairman of Novo Nordisk Pharma Ltd. from 2005 to 2007.
He also worked as an Independent Non-Executive Director at Proteomics International Laboratories Ltd. from 2016 to 2024.
Additionally, he was a Member-Management Board at Novo Nordisk A. Mr. Moore completed his undergraduate degree at The University of Sydney.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/11/2024 | 975 824 ( 0,59 % ) | 77 744 $ | 30/06/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
| PROTEOMICS INTERNATIONAL LABORATORIES LTD | Directeur/Membre du Conseil | 08/11/2024 |
Novo Nordisk Pharma Ltd.
Novo Nordisk Pharma Ltd. Pharmaceuticals: MajorHealth Technology Produces drugs and insulins | Président | 01/01/2007 |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
The University of Sydney
The University of Sydney Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Nordisk Pharma Ltd.
Novo Nordisk Pharma Ltd. Pharmaceuticals: MajorHealth Technology Produces drugs and insulins | Health Technology |
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd. Medical/Nursing ServicesHealth Services Provides biological research and drug discovery services | Health Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national